SOPHiA GENETICS’ Post

🔬 Enhancing Cancer Research at ASCO with iNGENū! 🔬 As the #ASCO24 meeting approaches, iNGENū is poised to assist oncology-focused companies in overcoming the complexities of clinical trials and regulatory landscapes. We are dedicated to providing transformative solutions that streamline research, making cutting-edge cancer treatments more accessible and effective. 🌟 What iNGENū CRO Offers: Cost Efficiency: Dramatically reduce the costs of oncology trials, enabling more research with the same resources. Regulatory Expertise: Benefit from our deep understanding of FDA regulations to accelerate your path to market. Strategic Australian Advantages: Leverage our capabilities to take advantage of fast-track processes and significant R&D tax incentives for quicker trial advancement. 👥 We are enthusiastic about partnering with leaders in oncology. Let’s explore how our innovative approaches can support your clinical and regulatory strategies for cancer research. #ASCO #Oncology #ClinicalTrials #ASCO2024 #CancerResearch

Excited to share our viewpoint published in JAMA Oncology Vivek Subbiah, MD and I delve into leveraging modern clinical trial tools to enhance access to precision oncology clinical trials. While master protocols and basket trials have revolutionized how these trials are conducted, they fall short in improving trial access. This leads to significant enrollment challenges, affecting representation and even delays. We discuss how modern, decentralized, trial methods offer promising solutions to enhance trial access. #PrecisionOncology #clinicaltrials

While the FDA’s Project Frontrunner guidance aims to expand access to a wider patient population, it also represents a major paradigm shift in regulatory guidance. When moving oncology drug development into earlier stages of disease, oncology drug developers will be expected to significantly adapt their trial design. Learn how partnering with IQVIA can help you navigate the changing landscape and bring novel therapies to cancer patients faster. https://bit.ly/3ZkNoJg #oncology #drugdevelopment

We believe African genomic diversity, insights, and expertise must be an integral part of precision oncology research, diagnostics, and therapeutics, for the benefit of patients everywhere.  Join us February 28th, 8 AM PT / 11 AM ET / 4 PM GMT as we explore why and how we can realize this vision. Register here: https://lnkd.in/gC79Fqjg #oncology #cancergenomics #healthequity

For those #regulatoryaffairs folks who missed Pistoia Alliance's excellent round-table last week, you can watch it here: https://lnkd.in/eFFc78ch. It was great to see the 'Regulatoria' work Jean-Pierre Doan and team are spearheading at Merck Group; listen to some very interesting discussion among industry veterans Rita Algorri, Colin Wood, and see the work from the In Vitro Pharmacology Working Group (a novel public-private partnership between the FDA and Pistoia Alliance). We at Datum are working on a product to structure, streamline, and fast-track regulatory approvals for non-small cell lung cancer immunotherapies and would love to hear from pharma colleagues who are interested in learning more. Please register your interest here: https://lnkd.in/eNM3wGbw. #NSCLC #immunotherapy #cancer #oncology #regulatoryaffairs #regulatorysubmissions

It is not just adhering to new policies but also finding the best way to adapt and best put into practice new approaches and regulations to ensure success in delivering therapies to the patients in the most efficient way.

Oncology clinical trials are becoming more global. Responding to a shift, the FDA issued draft guidance “Considerations for Generating Clinical Evidence from Oncology Multiregional Clinical Development Programs” aimed at helping the industry conduct global cancer clinical trials more effectively. The aim is to provide sponsors with recommendations when planning, designing, and conducting multiregional clinical trials (MRCTs) in support of marketing applications for cancer drugs in the US. Louise Scott PhD explains the draft guidance and provides key points for navigating MRCTs. https://hubs.li/Q02T-85p0 #FDAGuidance #OncologyTrials #Regulatory #GlobalTrials #MRCT

Trends in Oncology Clinical trials; Cancer treatments are improving what is possible for patients, with the use of technology in clinical trials bringing breakthroughs a step closer to becoming a reality. In this document we will outline four key trends within oncology and highlight the importance of biospecimens, which are becoming an increasing feature of clinical trials to treat cancer. Expert input will be provided by pharma logistics specialists, Oximio, based on experience of keeping biospecimens at the strict temperatures required. #pharmaindustry #pharmanews #pharmaceuticalindustry #clinicaltrials #clinicalresearch #oncologyresearch #oncologytrials #oncology #clinicaldevelopment #clinicalsolutions #clinicalsupply #clinicalstudies #clinicalservices

📸 Are Antibody-Drug Conjugates (#ADCs) planning to take the spotlight in 2024?! 🧠 Despite initial promise and a noticeable disillusionment phase, #ADCs have now emerged as a significant bright spot in #oncology research, brimming with untapped potential. 🌎 During the #JPMorgan2024 event, Daiichi Sankyo, Inc. and CEO Ken Keller presented a compelling story that highlighted the company's strategic pivot toward #oncology, emphasizing the significant opportunities within the field of #ADCs. 👨🔬 The substantial rise in #trials, soaring from 32 in 2013 to over 300 last year, vividly showcases the swift elevation of #ADCs, now recognized as the "cutting-edge" phenomenon with boundless potential. JP Morgan's 2024 report emphasized the industry's keen interest in #oncology, with #ADCs emerging as a prime focus for potential buyers and featuring prominently in major deals. Such as, MSD's $4bn agreement with Daiichi Sankyo, Inc. securing access to three drug candidates, in October. 🤔 Does this remarkable surge in #ADC trials signal a transformative era for oncology research? https://lnkd.in/eJxCVrPx

What if one day we could say cancer is behind us?      In close partnership with our colleagues in Oncology, our Discovery, Product Development & Supply teams are working relentlessly to push the bounds of science and create a healthier future.   We seek to understand cancer on a molecular level. Using every available tool in our multi-modality toolkit, our goal is to unlock the most promising therapeutic targets and invent transformative treatments across our Oncology pipeline.       Watch for more on how Johnson & Johnson Innovative Medicine is leading where medicine is going: https://bit.ly/3lKiJTV   #WorldCancerDay #InFrontofCancer